Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Benzinga Newsdesk www.benzinga.com Neutral 51.5%

Neg 0% Neu 51.5% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.